Deep Vein Thrombosis Market

Market Overview:

The 7 major deep vein thrombosis markets reached a value of USD 487.9 Million in 2024. Looking forward, IMARC Group expects the 7MM to reach USD 966.9 Million by 2035, exhibiting a growth rate (CAGR) of 6.42% during 2025-2035.

The deep vein thrombosis market has been comprehensively analyzed in IMARC's new report titled "Deep Vein Thrombosis Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2025-2035". Deep vein thrombosis (DVT) refers to a medical condition characterized by the formation of a blood clot in a deep vein, most commonly in the leg. This can happen when blood flow is slowed down or blocked, allowing blood cells and platelets to stick together and form a clot. The symptoms of the ailment vary depending on the intensity and location of the blood clot, but typical signs include swelling, pain, tenderness in the affected area, etc. If the blood clot reaches the lungs and causes a pulmonary embolism, several indications may appear, such as shortness of breath, chest pain, rapid breathing, coughing up blood, etc. Diagnosing deep vein thrombosis typically involves a physical examination, medical history review, and diagnostic tests. During a physical exam, a healthcare provider will look for signs of swelling, pain, and tenderness in the affected area. They may use a handheld Doppler device to listen for changes in blood flow. Various other procedures, such as a D-dimer blood test or venous ultrasound, are also utilized to confirm the diagnosis.

The rising cases of venous stasis owing to several causes, such as prolonged immobility, recent surgery, pregnancy, obesity, etc., are primarily driving the deep vein thrombosis market. In addition to this, the growing prevalence of various associated risk factors, including medical conditions that increase the likelihood of blood clotting, family history of blood clots, use of certain drugs like hormonal birth control, etc. Moreover, the escalating utilization of numerous anticoagulant medications, such as apixaban, rivaroxaban, dabigatran, etc., for preventing the formation of new blood clots and reducing the chances of existing clots getting bigger is also creating a positive outlook for the market. Apart from this, the widespread adoption of compression stockings as a preventative measure or as part of the treatment to improve blood flow is further bolstering the market growth. Additionally, the emerging popularity of inferior vena cava (IVC) filters among patients who cannot tolerate anticoagulant therapy, are at a high risk of bleeding, or have a recurrent DVT despite adequate anticoagulation is acting as another significant growth-inducing factor. Furthermore, the shifting preferences from traditional anticoagulants towards novel anticoagulants, such as betrixaban and edoxaban, owing to their numerous benefits including fewer drug interactions and more convenient dosing schedules, are expected to drive the deep vein thrombosis market in the coming years.

IMARC Group's new report provides an exhaustive analysis of the deep vein thrombosis market in the United States, EU4 (Germany, Spain, Italy, and France), United Kingdom, and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report, the United States has the largest patient pool for deep vein thrombosis and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario, unmet medical needs, etc., have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the deep vein thrombosis market in any manner.

Recent Developments:

• In February 2024, Bayer launched a Phase II clinical trial (SIRIUS study) for BAY3018250, a first-in-class anti-alpha2 antiplasmin (anti-α2ap) antibody in patients with deep vein thrombosis. BAY3018250 inhibits α2ap, a plasmin inhibitor that plays a crucial role in blood coagulation and dissolves clots in situ.
• In November 2023, Anthos Therapeutics, Inc., reported during a Late-Breaking session of the American Heart Association (AHA) meeting that abelacimab showed a highly significant reduction in bleeding events across all primary and secondary endpoints when compared to a standard of care direct-oral anticoagulant (DOAC).
• In June 2023, Inari Medical announced the launch of the RevCore thrombectomy catheter, the first mechanical thrombectomy device developed to treat venous in-stent thrombosis. This device features a diameter-controlled coring member that engages thrombus within stents.

Key Highlights:

• DVT is one of the most common medical disorders, with an annual incidence of 80 per 100,000 people.
• In the United States, around 600,000 people are hospitalized each year for DVT.
• In India, the overall incidence of DVT is approximately 1.79 per thousand people.
• After the age of 40 years, the risk of developing DVT may double with each passing decade.
• The male-to-female ratio is 1.2:1, indicating that men are more likely to develop DVT than women.

Drugs:

FRAGMIN prevents blood clots from developing in blood arteries. This medication is used to treat deep vein thrombosis, a type of blood clot in the legs. FRAGMIN belongs to a class of medications known as low molecular weight heparins (LMWHs). These medications function by decreasing blood clotting activity. FRAGMIN is administered via injection, either subcutaneously or intravenously.

ELIQUIS (apixaban) is recommended for the prevention of deep vein thrombosis, which can lead to pulmonary embolism (PE) in patients who have undergone hip or knee replacement surgery. It is an oral, selective Factor Xa inhibitor. Eliquis reduces thrombin synthesis and blood clot formation by blocking Factor Xa, an important blood-clotting protein.

Abelacimab is a highly selective, completely human monoclonal antibody. Abelacimab has dual activity: it binds to both the inactive and active versions of the clotting factor, causing significant inhibition of factor XI.

Time Period of the Study

• Base Year: 2024
• Historical Period: 2019-2024
• Market Forecast: 2025-2035
   

Countries Covered

• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan
   

Analysis Covered Across Each Country

• Historical, current, and future epidemiology scenario
• Historical, current, and future performance of the deep vein thrombosis market
• Historical, current, and future performance of various therapeutic categories in the market
• Sales of various drugs across the deep vein thrombosis market
• Reimbursement scenario in the market
• In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current deep vein thrombosis marketed drugs and late-stage pipeline drugs.

In-Market Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

Late-Stage Pipeline Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:

Market Insights

• How has the deep vein thrombosis market performed so far and how will it perform in the coming years?
• What are the markets shares of various therapeutic segments in 2024 and how are they expected to perform till 2035?
• What was the country-wise size of the deep vein thrombosis market across the seven major markets in 2024 and what will it look like in 2035?
• What is the growth rate of the deep vein thrombosis market across the seven major markets and what will be the expected growth over the next ten years?
• What are the key unmet needs in the market?
   

Epidemiology Insights

• What is the number of prevalent cases (​2019-2035​) of deep vein thrombosis across the seven major markets?
• What is the number of prevalent cases (​2019-2035​) of deep vein thrombosis by age across the seven major markets?
• What is the number of prevalent cases (​2019-2035​) of deep vein thrombosis by gender across the seven major markets?
• How many patients are diagnosed (​2019-2035​) with deep vein thrombosis across the seven major markets?
• What is the size of the deep vein thrombosis patient pool (2019-2024) across the seven major markets?
• What would be the forecasted patient pool (2025-2035) across the seven major markets?
• What are the key factors driving the epidemiological trend of deep vein thrombosis?
• What will be the growth rate of patients across the seven major markets?
   

Deep Vein Thrombosis: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

• What are the current marketed drugs and what are their market performance?
• What are the key pipeline drugs and how are they expected to perform in the coming years?
• How safe are the current marketed drugs and what are their efficacies?
• How safe are the late-stage pipeline drugs and what are their efficacies?
• What are the current treatment guidelines for deep vein thrombosis drugs across the seven major markets?
• Who are the key companies in the market and what are their market shares?
• What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the deep vein thrombosis market?
• What are the key regulatory events related to the deep vein thrombosis market?
• What is the structure of clinical trial landscape by status related to the deep vein thrombosis market?
• What is the structure of clinical trial landscape by phase related to the deep vein thrombosis market?
• What is the structure of clinical trial landscape by route of administration related to the deep vein thrombosis market?